Category Archive: Uncategorized

Dec
07

Getting to an in vivo active compound

Its been an incredibly fast paced year and hence my posting frequency has suffered. Perhaps its time to get back to writing . Today we had a press release with SRI so that triggered me to fill in the back story. Rewind back to 2014 and the Ebola outbreak was in full flow – see …

Continue reading »

Jan
18

Post doctoral position on chaperone development for neurological disorders

I would like to highlight an open postdoc position in the lab of a close collaborator Dr. Alexey Pshezhetsky Open position: Postdoctoral fellow or Ph.D. student Supervising researcher and laboratory: Dr. Alexey Pshezhetsky, laboratory studying lysosomal biology and metabolic disorders, Research Center of CHU Sainte-Justine Project length: 1 year with renewal opportunity Start date: Immediately …

Continue reading »

Nov
07

Non-classical transpeptidases insights and new antibacterials

Well today’s post has been a few years in gestation and yes I have had to keep it quiet for a long, long time which was extended as our recent paper was embargoed for what seemed like an eternity. It starts back in 2009 when I was using some of the NIAID/SRI whole cell screening …

Continue reading »

Oct
18

Zika Homology models paper makes it to PubMed >6 months after “Publishing” in F1000Research

Who would have thought in February that when we submitted our manuscript on Zika homology models to F1000Research it would finally appear in PubMed over 6 months later. This was no where near as fast as our first article on Zika that took a few months to be approved and then appear in PubMed. What …

Continue reading »

Sep
20

Progress Through Partnership: The NINDS 2016 Nonprofit Forum

Last tuesday and wednesday (Sept 13-14th)  I was very honored to be an attendee at the “Progress Through Partnership: The NINDS 2016 Nonprofit Forum“. My role was to provide an industry perspective on several panels (alongside Dr. Ronald Marcus, Cerecor). There were a large number of rare disease (patients or parent) advocates, academic scientists and …

Continue reading »

Jun
24

BIO2016 and getting Big Pharma to listen to the patient’s voice..

Its hard to believe that a couple of weeks ago BIO2016 was coming to an end. After 5 days in San Francisco my legs were tired, my voice was rough, and I was tired of boxed lunches and eating dinner at crazy irregular times – generally very late. Its a hard life! I was at …

Continue reading »

Jan
20

Where will BIA 10-2474 lead us?

**UPDATE As of 21st Jan 2016 please note the actual structure of BIA 10-2474 changed to this. My “Armchair science” / speculative contributions on this blog for the clinical trial disaster with BIA 10-2474 got a bit of notice over the past few days at Forbes and C&E News. There have also been discussions with …

Continue reading »

Jan
16

What can we predict about BIA 10-2474

**UPDATE As of 21st Jan 2016 please note the actual structure of BIA 10-2474 changed to this.   In the past few days we learnt about the clinical trial that went terribly wrong in France leaving several volunteers in a very serious condition. In involves a compound from a company called Bial and the compound …

Continue reading »

Oct
15

ninth chapel hill pharmaceutical sciences conference

Today I am at a local conference at UNC and you can find me live tweeting under #PharmSci15 . Conference link is here.

Jul
30

My experience of submitting another manuscript to PLOSONE

Its been several years since I last submitted to PLOSONE . Since then we embarked on a Phase II grant working on tuberculosis and after much work by many labs at Rutgers and SRI we are now submitting the work today. So we decided to give PLOSONE a second chance. In the interim I have …

Continue reading »

Older posts «